0.00Open2.00Pre Close0 Volume93 Open Interest220.00Strike Price0.00Turnover48.56%IV6.85%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry2.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1544Delta0.0149Gamma170.20Leverage Ratio-0.2621Theta-0.0069Rho-26.29Eff Leverage0.0780Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet